Arrowhead Pharmaceuticals
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 525
- Market Cap
- $2.9B
- Introduction
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Ste...
Study of ARO-RAGE in Healthy Subjects
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT05533294
- Locations
- ๐ณ๐ฟ
Research Site, Grafton, Aukland, New Zealand
Study of ARO-APOC3 in Adults With Dyslipidemia
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 418
- Registration Number
- NCT05413135
- Locations
- ๐บ๐ธ
Preventive Cardiology Inc., Boca Raton, Florida, United States
๐บ๐ธA&R Research Group, Pembroke Pines, Florida, United States
๐บ๐ธAlta Pharmaceutical Research Center, Dunwoody, Georgia, United States
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 78
- Registration Number
- NCT05292950
- Locations
- ๐ฆ๐บ
Mater Hospital, South Brisbane, Queensland, Australia
๐ฆ๐บInstitute For Respiratory Health - Perth, Nedlands, Australia
๐ฐ๐ทThe Catholic University of Korea Bucheon St. Mary's Hospital, Bucheon, Gyeonggi-do, Korea, Republic of
Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 275
- Registration Number
- NCT05276570
- Locations
- ๐ฆ๐บ
Mater Hospital, South Brisbane, Queensland, Australia
๐ฆ๐บInstitute for Respiratory Health-Perth, Nedlands, Western Australia, Australia
๐ฐ๐ทJeonbuk National University Hospital, Jeonju, Korea, Republic of
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT05217667
- Locations
- ๐บ๐ธ
Icahn School of Medicine at Mt. Sinai, Mount Sinai, New York, United States
๐บ๐ธMetabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States
๐ฆ๐บLinear Clinical Research, Nedlands, Western Australia, Australia
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 75
- Registration Number
- NCT05089084
- Locations
- ๐ต๐ฑ
Instytut Centrum Zdrowia Matki Polki, ลรณdลบ, Poland
๐บ๐ธExcel Medical Clinical Trials, LLC, Boca Raton, Florida, United States
๐บ๐ธAscension St. Vincent Cardiovascular Research Institute, Indianapolis, Indiana, United States
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05083364
- Locations
- ๐ฌ๐ง
Research Site 1, Leicester, United Kingdom
๐ฌ๐งResearch Site 3, Liverpool, United Kingdom
๐ฌ๐งResearch Site 2, Coventry, United Kingdom
Study of ARO-APOC3 in Adults With Mixed Dyslipidemia
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 353
- Registration Number
- NCT04998201
- Locations
- ๐บ๐ธ
Alta Pharmaceutical Research Center, Dunwoody, Georgia, United States
๐บ๐ธPreventive Cardiology Inc., Boca Raton, Florida, United States
๐บ๐ธA & R Research Group, Pembroke Pines, Florida, United States
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 204
- Registration Number
- NCT04832971
- Locations
- ๐บ๐ธ
Baylor College of Medicine, Houston, Texas, United States
๐บ๐ธAGA Clinical Trials, Hialeah, Florida, United States
๐บ๐ธMedication Management LLC, Greensboro, North Carolina, United States
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 229
- Registration Number
- NCT04720534
- Locations
- ๐บ๐ธ
Pioneer Research Solutions, Inc., Houston, Texas, United States
๐บ๐ธClinical Research of South Nevada, Las Vegas, Nevada, United States
๐บ๐ธAppleMed Research Group, Miami, Florida, United States